Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Research note: A 2025 literature and patent review catalogued BPC-157's multifunctional activity across gastrointestinal, musculoskeletal, neurological, and cardiovascular preclinical models
No published trial preclinical or human has tested the combination
With a high concentration of vitamins, IV therapy can strengthen the immune system and provide faster relief
The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
[8] In summary, TB-500, as a functional fragment of T4, holds potential for supporting intestinal repair by enhancing epithelial regeneration, reducing inflammation, and stabilizing the gut barrier
US$ 29.80
US$ 29.39
US$ 22.78
US$ 20.17
US$ 26.33
US$ 22.27
US$ 27.28
